EMA recommends marketing approval for Amgen Europe’s Tepezza to treat adults with moderate to severe thyroid eye disease: Amsterdam, The Netherlands Monday, April 28, 2025, 11:0 ...

Aurobindo Pharma's biosimilar for breast cancer recommended for EU approval, demonstrating similarity to Herceptin.

Onward Therapeutics SA’s subsidiary Emercell SAS has received investigational medicinal product dossier (IMPD) approval from the EMA to initiate a phase I trial of OT-C001, an allogeneic natural ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ ...

Expert advisers including neurologists and patient representatives have expressed concern at the European Commission’s (EC) decision to formally approve the Alzheimer’s drug lecanemab (Leqembi) ...

EPALINGES, Switzerland and PARIS, April 22, 2025 /PRNewswire/ — Onward Therapeutics SA, a biotechnology company dedicated to advancing innovative cancer immunotherapies, announced that its subsidiary, ...

Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated ...

The EMA "concluded that the benefits of this medicine outweighed the risks, in a particular population of patients with such disease and as long as risk minimisation measures are applied," the ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...

The European Commission (EC) has at last granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing ...